The PI3K/Akt signaling pathway dysregulation is effectively involved in cancer onset and progression, making this pathway an interesting target for therapeutic intervention.34,35 In this regard, development of new therapeutic strategies against ALL cells for negative modulation of PI3K/Akt signaling is extremely important to achieve better clinical outcomes and restore the functional balance between tumor suppressors and growth signaling pathways. This evidence concerns the gene AKT1 and acute lymphoblastic leukemia.